Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
Cardiovascular disease (CVD) burden remains the predominant cause of mortality and morbidity in the United States and in most of the developed world. The ongoing twin epidemics of obesity and type 2 diabetes mellitus provide a groundswell source for sustaining this trend for the foreseeable future (increasing the prevalence of CVD by 2-4 times), unless radical changes are made in public health policy. Oral hypoglycemic agents (OHAs) remain a mainstay for management of type 2 diabetes in most practice settings. Although these agents are primarily prescribed to achieve better glycemic control, it is important to evaluate what effects they have on cardiovascular risk and whether there are significant differences in effects among the different OHAs. This review presents the available data on the effects of the various OHAs on cardiovascular risk surrogates and actual events in retrospective and prospective study design settings.
Uwaifo
Gabriel I
GI
Georgetown University College of Medicine, Washington, District of Columbia 20003, USA. gabriel.uwaifo@medstar.net
Ratner
Robert E
RE
D000284:Administration, Oral; D001549:Benzamides / Q000494:pharmacology; D001645:Biguanides / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology
D001549:Benzamides; D001645:Biguanides; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C030516:meglitinide